Viatris will acquire Pacira BioSciences for $1.65 billion in an all-shares deal, according to the transaction outline. The purchase adds two established pain products: Exparel bupivacaine for acute postsurgical pain and Zilretta sustained-release triamcinolone for osteoarthritis pain. The products generated $350.5 million in revenue across the first six months of 2026, with Exparel accounting for the majority of that figure. The acquisition is positioned as a way for Viatris to deepen its non-opioid analgesics franchise at a time when health systems scrutinize opioid exposure. For the biotech and pharma pipeline ecosystem, the deal also reflects how established commercial products are being used to stabilize earnings and fund later-stage or platform investments amid unpredictable financing conditions.